6515--NanoKnife 3.0 Irreversible Electroporation (IRE) System
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically NCO 1, has awarded a firm-fixed contract to Marathon Medical Corporation for the NanoKnife 3.0 Irreversible Electroporation (IRE) System, valued at $433,417.09. This award, made on April 9, 2026, procures a critical medical device for the West Haven VAMC.
Scope of Work
This contract is for the procurement of a NanoKnife 3.0 Irreversible Electroporation (IRE) System. This advanced medical device utilizes a non-thermal method to ablate tumor cells while preserving surrounding healthy tissue, making it particularly suitable for treating tumors located near vital structures. The new system replaces an older model (NanoKnife System 2.2.1) that had reached its end of life and was no longer supported by the Original Equipment Manufacturer (OEM), Angiodynamics, posing safety concerns.
Contract & Timeline
- Type: Firm-Fixed Contract
- Value: $433,417.09
- Award Date: April 9, 2026
- Awardee: Marathon Medical Corporation (UEI: YNGKKQWQLKC9)
- Contracting Office: Department of Veterans Affairs, NCO 1, West Haven, CT
Set-Aside & Justification
This acquisition was conducted as a sole source procurement under the Multiple-Award Schedule Program, justified by an "urgent and compelling need" and the unique nature of the Angiodynamics IRE device. Marathon Medical Corporation was identified as the Sole Authorized SDVOSB Distributor for AngioDynamics products to the VA, aligning with GSAM/R 538.7104-3(b). Market research confirmed their exclusive reseller status for this specialized equipment.
Additional Notes
The justification highlighted that no other IRE device has comparable clinical data in prostate cancer, reinforcing the necessity for the Angiodynamics product. The procurement addresses an immediate safety concern due to the malfunction and end-of-life status of the previous system.